BioXcel Therapeutics, Inc. BTAIQ

BTAIQ Company Overview

BioXcel Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing medicines in neuroscience and immuno-oncology through the application of artificial intelligence-driven drug innovation. The company operates at the intersection of biotechnology and data science, using proprietary computational approaches to identify and advance existing or partially characterized compounds for new therapeutic indications. BioXcel Therapeutics is publicly traded on Nasdaq under the ticker BTAI and was formed as a subsidiary spinout from BioXcel LLC, an AI-enabled drug discovery company.

The company’s primary business focus has centered on neuroscience therapeutics, particularly acute care and neuropsychiatric disorders. Its lead commercial product is IGALMI (dexmedetomidine) sublingual film, approved in the United States for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Historically, the company also pursued immuno-oncology development programs, although strategic emphasis has increasingly shifted toward neuroscience and hospital-based behavioral health applications. BioXcel Therapeutics positions itself through its AI-enabled drug re-innovation platform, which seeks to reduce development timelines and costs by leveraging existing pharmacological and clinical data.